Special Issue "Liquid Biopsies in Cancer Diagnosis, Monitoring and Prognosis"

A special issue of Biomedicines (ISSN 2227-9059).

Deadline for manuscript submissions: 31 October 2020.

Special Issue Editors

Dr. Stefano Indraccolo
Website
Guest Editor
Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy
Interests: Translational research; lung cancer and ovarian cancer; Notch signaling in cancer; tumor angiogenesis and metabolism; mechanisms of resistance to antiangiogenic therapy; prognostic/predictive biomarker identification
Special Issues and Collections in MDPI journals
Dr. Paola Ulivi
Website
Guest Editor
Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, 47014 Meldola, Italy
Interests: translational research; targeted therapy; biomarkers; liquid biopsy; colorectal cancer
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

Liquid biopsy has emerged as new tool for detecting clinically relevant genetic alterations in cancer patients. The term liquid biopsy is commonly used not only to refer to molecular assays performed on cell-free DNA purified from plasma but can also include testing on other body fluids, such as urine and cerebrospinal fluid and measurements of circulating tumor cells, exosomes and circulating tumor RNA.

Here, we would like to focus on liquid biopsy approaches to track response to therapy in solid tumors. This special issue will cover studies investigating the significance of liquid biopsy for diagnostic/prognostic purposes as well as to predict patient outcome, compared with patient management guided via canonical molecular data and imaging modalities.

In this Special Issue, we welcome Original Research and Review articles focused on, but not limited to, dynamic measurements of mutations and other genetic alterations in plasma or other fluids. Studies on other liquid biopsy biomarkers such as microRNA and proteins are also considered.

Dr. Stefano Indraccolo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
When Less Is More: Specific Capture and Analysis of Tumor Exosomes in Plasma Increases the Sensitivity of Liquid Biopsy for Comprehensive Detection of Multiple Androgen Receptor Phenotypes in Advanced Prostate Cancer Patients
Biomedicines 2020, 8(5), 131; https://doi.org/10.3390/biomedicines8050131 - 22 May 2020
Abstract
We evaluated the advantages and the reliability of novel protocols for the enrichment of tumor extracellular vesicles (EVs), enabling a blood-based test for the noninvasive parallel profiling of multiple androgen receptor (AR) gene alterations. Three clinically relevant AR variants related to response/resistance [...] Read more.
We evaluated the advantages and the reliability of novel protocols for the enrichment of tumor extracellular vesicles (EVs), enabling a blood-based test for the noninvasive parallel profiling of multiple androgen receptor (AR) gene alterations. Three clinically relevant AR variants related to response/resistance to standard-of-care treatments (AR-V7 transcript, AR T878A point mutation and AR gene amplification) were evaluated by digital PCR in 15 samples from patients affected by Castration-Resistant Prostate Cancer (CRPC). Plasma was processed to obtain circulating RNA and DNA using protocols based on tumor EVs enrichment through immuno-affinity and peptide-affinity compared to generic extraction kits. Our results showed that immuno-affinity enrichment prior to RNA extraction clearly outperforms the generic isolation method in the detection of AR-V7, also allowing for a distinction between responder (R) and non-responder (NR) patients. The T878A mutation was detected, overall, in nine out of 15 samples and no approach alone was able to reveal mutations in all harboring samples, showing that the employed methods complement each other. AR amplification was detected in the majority of CRPC samples analysed using either cell-free DNA (cfDNA) or exosome isolation kits (80%). We demonstrated that selective isolation of a subset of circulating exosomes enriched for tumor origin, rather than analysis of total plasma exosomes, or total plasma nucleic acids, increases sensitivity and specificity for the detection of specific alterations. Full article
(This article belongs to the Special Issue Liquid Biopsies in Cancer Diagnosis, Monitoring and Prognosis)
Show Figures

Figure 1

Back to TopTop